Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening

Madanahally D. Kiran, Nallini Vijayarangan Adikesavan, Oscar Cirioni, Andrea Giacometti, Carmela Silvestri, Giorgio Scalise, Roberto Ghiselli, Vittorio Saba, Fiorenza Orlando, Menachem Shoham, Naomi Balaban

Research output: Contribution to journalArticlepeer-review

Abstract

Staphylococci are a major health threat because of increasing resistance to antibiotics. An alternative to antibiotic treatment is preventing virulence by inhibition of bacterial cell-to-cell communication using the quorum-sensing inhibitor RNAIII-inhibiting peptide (RIP). In this work, we identified 2′,5-di-O-galloyl-D-hamamelose (hamamelitannin) as a nonpeptide analog of RIP by virtual screening of a RIP-based pharmacophore against a database of commercially available small-molecule compounds. Hamamelitannin is a natural product found in the bark of Hamamelis virginiana (witch hazel), and it has no effect on staphylococcal growth in vitro; but like RIP, it does inhibit the quorum-sensing regulator RNAIII. In a rat graft model, hamamelitannin prevented device-associated infections in vivo, including infections caused by methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis strains. These findings suggest that hamamelitannin may be used as a suppressor to staphylococcal infections.

Original languageEnglish
Pages (from-to)1578-1586
Number of pages9
JournalMolecular Pharmacology
Volume73
Issue number5
DOIs
Publication statusPublished - May 2008

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening'. Together they form a unique fingerprint.

Cite this